> Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Reshma L. Mahtani, DO

Date and Time

Thu, Oct 07, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording

Event details

Understanding your breast cancer diagnosis, treatment, and potential side effects can be overwhelming. In this video, Reshma L. Mahtani, DO, answers questions about breast cancer treatment options, recent drug approvals, immunotherapy, as well as symptoms and side effects for early stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer.

Date and Time

Thu, Oct 07, 2021 7:00 pm to 8:00 pm ET

Location

Virtual

Watch session recording
speakers_feature

About our expert:

Reshma L. Mahtani, DO

Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She is an associate professor of medicine at the University of Miami, Sylvester Comprehensive Cancer Center in Deerfield Beach, Florida. She is co-leader of the breast cancer program and director of community outreach.

Read full bio
upcoming_events

Upcoming Events

Ask the expert: Metastatic breast cancer

Wed, Dec 14, 2022

Learn More

Thriving Together: 2023 Conference on Metastatic Breast Cancer

Fri, Apr 28, 2023

Learn More
related_resources_article_carousel

Related articles

Abemaciclib

07/25/22 | BY: Tiffany Avery

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Read More | 8 Min. Read

Targeted therapy for hormone-receptor positive breast cancer

07/25/22 | BY: Tiffany Avery

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal therapy is a type of targeted therapy because it targets hormones that are active in cancer growth.

Read More | 6 Min. Read

HER2-positive

05/05/22 | BY: Reshma L. Mahtani

If you are diagnosed with HER2-positive breast cancer, you may be wondering what that means. Read about the ins-and-outs of HER2-positive breast cancer.

Read More | 14 Min. Read |

Hormone receptor-positive

05/04/22 | BY: Reshma L. Mahtani

Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones occur naturally in the body and prompt cell action in different ways.

Read More | 15 Min. Read |

Neratinib

03/25/21 | BY: Tiffany Avery

Neratinib (Nerlynx) is a targeted therapy for people with HER2-positive breast cancer. It is the first medicine for people with HER2-positive breast cancer approved as extended therapy, meaning that for early-stage disease, it is given after primary treatment ends to lower the risk of cancer coming back.

Read More | 6 Min. Read

Pertuzumab

03/25/21 | BY: Tiffany Avery

Pertuzumab (Perjeta) is a targeted therapy used to treat early-stage and metastatic HER2-positive breast cancer. Pertuzumab is a monoclonal antibody, a type of medicine made in a lab that targets a specific protein, HER2, produced on the outside of a cell. It falls in a class of medicines called targeted therapies.

Read More | 6 Min. Read

Trastuzumab

03/25/21 | BY: Tiffany Avery

The medicine trastuzumab (Herceptin and biosimilars) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a specific protein produced on the outside of a cell. It falls in a class of medicines called targeted therapies.

Read More | 7 Min. Read

Tucatinib

03/25/21 | BY: Tiffany Avery

Tucatinib (Tukysa) is a tyrosine kinase inhibitor used to treat metastatic, HER2-postive breast cancer. It is given with another targeted therapy, trastuzumab (Herceptin), and the chemotherapy pill capecitabine (Xeloda) to treat cancers that have grown after previous HER2-targeted treatments.

Read More | 5 Min. Read

Margetuximab

02/12/21 | BY: Virginia Kaklamani

Margetuximab (Margenza) is a medicine approved by the Food and Drug Administration to be given with chemotherapy to treat metastatic, HER2-positive breast cancer after treatment with at least two previous lines of targeted therapy.

Read More | 5 Min. Read

Hormone receptor-positive MBC

11/22/19 | BY: Christina Brus

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More | 6 Min. Read
stay_connected

Stay Connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.

[item.name]
[item.name]
[item]
[item]
[class^="wpforms-"]
[class^="wpforms-"]
[item.name]
[item.name]
[item]
[item]